Table 4.

Clinical trials of single-agent romidepsin in lymphoproliferative disorders.

Study (year)	Phase	Disease	Patients (n)	Responses	Ref.
Byrd et al.(2005)	I	CLL	10	No PR/CR (see text)	[87]
Whittaker et al.(2010)	II	CTCL	96	6 CR; 27 PR; 45 SD	[2]
Piekarz et al.(2009)	II	CTCL	71	4 CR; 20 PR; 26 SD	[3]
Piekarz et al.(2011)	II	PTCL	45	8 CR; 9 PR; 5 SD	[101]
Niesvizky et al.(2011)	II	MM	12	11 SD	[106]

CLL: Chronic lymphocytic leukemia; CR: Complete response; CTCL: Cutaneous T-cell lymphoma; MM: Multiple myeloma;

PR: Partial response; PTCL; Peripheral T-cell lymphoma; SD: Stable disease.